Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vir Biotechnology Inc. Common Stock (VIR) vs VNET Group Inc (VNET) Price & Performance

Vir Biotechnology Inc. Common StockTrade
VNET Group IncTrade

Price performance (Past 24H)

Key statistics

Vir Biotechnology Inc. Common Stock vs VNET Group Inc — how do they compare? Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B), while VNET Group Inc trades at $4.54 (market cap $1.49B). The key difference: Vir Biotechnology Inc. Common Stock is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vir Biotechnology Inc. Common Stock for 0 Days and VNET Group Inc for 16 Days on average.

VIRVNET
Market Cap
$1.80B$1.49B
Volume
1,782,8363,619,133
Sector
HealthTechnology
52-Week High
$11.78$14.03
52-Week Low
$5.12$4.49
Typical Hold Time
0 Days16 Days
Enterprise Value
$1.36B$5.07B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

VNET Group Inc

VNET trades at $5.26, down 1.13% today, and has hit new 52-week lows recently. The technical outlook is bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.

The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately positive with a 'Buy' consensus. Key risks include balance sheet strain and competitive pressures in the data center market. Investment opportunity hinges on execution of growth initiatives and improvement in profitability metrics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VIR
51% Buy49% Sell
Avg holding period · 0 Days
VNET

No sentiment data available yet.

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →

About VNET Group Inc

VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.

Read more on VNET →